Rinzimetostat RP3D in Combination with Darolutamide selected for Himalayas-1 Ph 3 Global Study with Dose Optimization Data April 7, 2026
TALZENNA Plus XTANDI Significantly Improves Radiographic PFS in Metastatic Prostate Cancer March 24, 2026
ProstACT Ph 3 Study (Part 1) of TLX591-Tx Achieves Primary Objectives in PSMA+ve metastatic CRPC Patients March 17, 2026
European Commission approves AKEEGA (niraparib & abiraterone dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic HSPC patients March 10, 2026
Encouraging results for 225Ac-PSMA-Trillium in advanced metastatic prostate cancer reported March 3, 2026
Astellas and Vir Biotechnology to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer March 3, 2026
New real‑world data reinforce earlier use of Pluvicto before chemotherapy in metastatic CRPC March 3, 2026
Early study results show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer March 3, 2026
Candel Therapeutics’ $100M Royalty Funding Agreement with RTW to Support Aglatimagene Besadenovec (CAN-2409) Launch in Localized Prostate Cancer Announced February 25, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 1, 2026
Preliminary Results from Ph 2 Study of PDS01ADC in 3L Metastatic CRPC by the NCI to be presented February 1, 2026
CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for metastatic HSPC with BRCA1/2 mutations February 1, 2026
First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland Announced December 30, 2025
Clinical Activity of MRT-2359 + Enzalutamide Combo in Heavily Pretreated Metastatic CRPC Patients with Androgen Receptor Mutations Announced December 22, 2025
FDA approves AKEEGA® for BRCA2m metastatic CSPC with 54% reduction in disease progression vs SOC December 15, 2025
Encouraging Efficacy and Safety Profile from Ongoing Ph 1 Trial for JANX007 in mCRPC Announced December 9, 2025
Statistical analysis of primary efficacy endpoints in Ph 2 trial conducted of MCS-8 (PCP) in prostate cancer completed November 24, 2025
Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC October 29, 2025
US FDA Priority Review for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) in BRCA-mutated metastatic CSPC October 21, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
